EUCTR2005-001248-22-DK
Active, not recruiting
Phase 1
A prospective randomized multicentre study to compare Crinone 8% once daily versus other vaginal progesterone.
Fertilitetsklinikken Nordica0 sites2,686 target enrollmentSeptember 23, 2005
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fertilitetsklinikken Nordica
- Enrollment
- 2686
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women \<40 years who are under going IVF treatment and are willing to sign Informed Consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Women who are not willing to sign Informed Consent form.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A prospective randomized multicentre study to compare Crinone 8% once daily versus other vaginal progesterone.EUCTR2005-001248-22-SEFertilitetsklinikken Herlev Hospital2,686
Recruiting
Phase 2
A multicenter, prospective randomized study to compare vascular healing after deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) versus the Everolimus Eluting Stent in patients with Acute Coronary Syndrome by means of Optical Coherence TomographyAcute Coronary SyndromeHeart attack10011082NL-OMON36157OrbusNeich Medical B.V.20
Recruiting
Not Applicable
Comparison of IVF-ET outcomes with GnRH antagonist started either on stimulation day 1 and 6 vs. conventional GnRH agonist long protocol in patients with polycystic ovary syndromeEndocrine, nutritional and metabolic diseaseKCT0000157Seoul National University Hospital267
Not yet recruiting
Phase 4
Prospective, randomized, multicentre study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and/or worsening of previous vertebral fractures in women with a clinical vertebral fracture or recent hip fracture (imminent risk of fracture) caused by bone fragility.2025-521301-40-00Gedeon Richter Iberica S.A.127
Completed
Phase 4
*A prospective randomized multicenter study to demonstrate the superiority of the Barricaid® to discectomy for primary lumbar disc herniation*: Extended Follow-Up of the Barricaid® Annular Closure Device (ACD) Randomized Control Trial (RCT) Postmarket Cohort for Lumbar Disc Herniation and Interaction with Other Risk Factorslumbar disc herniationsciatica100432371004154310009720NL-OMON55882Intrinsic Therapeutics, GmbH66